Ardelyx, Inc. (ARDX) shareholders
Close on Nov 18, 2026Market cap $777.47MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Israel A. Englander Joint filing with Millennium Management LLC (7.40%), Millennium Group Management LLC (7.40%) and 1 more | 18,043,970 | 7.40% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 16,776,055 | 7.20% | 13G (passive) | Dec 31, 2023 |
| Rubric Capital Management LP Joint filing with David Rosen (6.56%) | 16,202,700 | 6.56% | 13G (passive) | Jun 30, 2026 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.70%), Israel A. Englander (5.70%) | 14,200,773 | 5.70% | 13G (passive) amendment | Jun 30, 2026 |
| State Street Corporation | 13,604,307 | 5.50% | 13G (passive) | Mar 31, 2026 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.10%), Israel A. Englander (5.10%) | 12,099,947 | 5.10% | 13G (passive) | Jun 17, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 23,504,630 | 9.43% | $119.87M | +2,340,498 | 0.00% |
| Rubric Capital Management LP | 16,202,700 | 6.50% | $82.63M | +14,341,804 | 0.76% |
| Millennium Management LLC | 13,900,773 | 5.58% | $70.89M | −3,941,597 | 0.03% |
| State Street Corp | 13,356,128 | 5.36% | $68.12M | −248,179 | 0.00% |
| Vanguard Capital Management LLC | 10,471,494 | 4.20% | $53.40M | +105,982 | 0.00% |
| Nomura Asset Management International Inc. | 9,546,732 | 3.83% | $48.69M | +1,377,363 | 0.07% |
| Vanguard Portfolio Management LLC | 8,026,774 | 3.22% | $40.94M | +1,365,081 | 0.00% |
| Geode Capital Management, LLC | 6,401,736 | 2.57% | $32.66M | +394,281 | 0.00% |
| Jupiter Topco LLC | 5,302,311 | 2.13% | $27.04M | New | 0.01% |
| Two Sigma Investments, LP | 5,209,823 | 2.09% | $26.57M | +935,780 | 0.02% |
| Nuveen, LLC | 3,997,099 | 1.60% | $20.39M | −1,237,584 | 0.00% |
| Goldman Sachs Group Inc | 3,685,034 | 1.48% | $18.79M | +468,824 | 0.00% |
| AIGH Capital Management LLC | 3,200,000 | 1.28% | $16.32M | New | 1.03% |
| Morgan Stanley | 2,389,546 | 0.96% | $12.19M | +680,573 | 0.00% |
| Aqr Capital Management LLC | 2,316,220 | 0.93% | $11.81M | −123,230 | 0.00% |
| Northern Trust Corp | 2,280,143 | 0.92% | $11.63M | +209,096 | 0.00% |
| Rock Springs Capital Management LP | 2,241,769 | 0.90% | $11.43M | −57,704 | 0.56% |
| Charles Schwab Investment Management Inc | 2,211,760 | 0.89% | $11.28M | +97,662 | 0.00% |
| Bank Of America Corp /De/ | 2,163,500 | 0.87% | $11.03M | −173,494 | 0.00% |
| Qube Research & Technologies Ltd | 2,090,675 | 0.84% | $10.66M | −344,873 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 249 | 177M | 71.2% | 44 / 88 | 87 / 34 | 39M | 23M |
| Q1 2026 | 242 | 170M | 68.1% | 50 / 106 | 59 / 32 | 47M | 24M |
| Q4 2025 | 229 | 167M | 67.0% | 37 / 79 | 84 / 26 | 31M | 26M |
| Q3 2025 | 223 | 164M | 65.6% | 40 / 78 | 73 / 20 | 21M | 25M |
| Q2 2025 | 206 | 168M | 67.4% | 30 / 78 | 64 / 43 | 27M | 24M |
| Q1 2025 | 221 | 165M | 66.1% | 43 / 89 | 55 / 33 | 33M | 18M |
| Q4 2024 | 213 | 151M | 60.7% | 46 / 76 | 61 / 34 | 21M | 13M |
| Q3 2024 | 203 | 143M | 57.4% | 30 / 76 | 66 / 22 | 31M | 15M |
| Q2 2024 | 197 | 145M | 58.0% | 42 / 67 | 62 / 33 | 19M | 21M |
| Q1 2024 | 189 | 147M | 58.9% | 54 / 62 | 55 / 26 | 28M | 21M |
| Q4 2023 | 162 | 141M | 56.4% | 38 / 70 | 34 / 25 | 28M | 13M |
| Q3 2023 | 150 | 126M | 50.5% | 31 / 53 | 37 / 25 | 27M | 27M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
165 funds held ARDX in Q2 2026, 53% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ARDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,416,791 | 2.98% | $37.83M | 0.35% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 7,404,867 | 2.97% | $37.76M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,362,240 | 2.55% | $32.45M | 0.04% | Jun 30, 2026 |
| Nomura Small Cap Core Fund | 6,265,909 | 2.51% | $37.85M | 0.69% | May 29, 2026 |
| Vanguard Extended Market Index Fund | 2,831,265 | 1.14% | $14.44M | 0.01% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 2,696,698 | 1.08% | $13.75M | 0.11% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,670,245 | 1.07% | $13.22M | 0.04% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,256,163 | 0.91% | $11.51M | 0.07% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 2,174,460 | 0.87% | $11.09M | 0.19% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,508,019 | 0.61% | $7.46M | 0.03% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 1,257,295 | 0.50% | $7.59M | 0.02% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,231,025 | 0.49% | $7.44M | 0.04% | May 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 1,192,550 | 0.48% | $5.90M | 0.15% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,166,243 | 0.47% | $7.04M | 0.03% | May 31, 2026 |
| Invesco Biotechnology & Genome ETF | 1,120,704 | 0.45% | $5.55M | 1.97% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Raab | President & CEO, Director | 1,639,970 | 0.66% | Aug 25, 2026 |
| Eric Duane Foster | Chief Commercial Officer | 409,410 | 0.16% | Aug 25, 2026 |
| John E. Bishop | See Remarks | 317,095 | 0.13% | Aug 25, 2026 |
| Susan Hohenleitner | Chief Financial Officer | 227,520 | 0.09% | Aug 25, 2026 |
| Mike Kelliher | Chief Business Officer | 351,662 | 0.14% | Aug 25, 2026 |
| Joseph James Reilly | See Remarks | 146,964 | 0.06% | Aug 25, 2026 |
| James Parker Brady | Chief Human Resources Officer | 259,090 | 0.10% | Aug 25, 2026 |
| Laura A. Williams | Chief Patient Officer | 371,620 | 0.15% | Aug 25, 2026 |
| Felecia Ettenberg | Chief Legal Officer | 237,000 | 0.10% | Apr 22, 2026 |
| Rajani Dinavahi | Chief Medical Officer | 201,000 | 0.08% | Apr 3, 2026 |
| Elizabeth A. Grammer | See Remarks | 302,866 | 0.12% | Nov 25, 2025 |
| Edward R. Conner | Chief Medical Officer | 302,260 | 0.12% | Oct 17, 2025 |
| Justin A. Renz | Chief Financial Officer | 409,052 | 0.16% | Aug 25, 2025 |
| Robert Blanks | See Remarks | 314,421 | 0.13% | Nov 22, 2024 |
| David P. Rosenbaum | Chief Development Officer | 525,970 | 0.21% | Nov 22, 2024 |
| Merdad Parsey | Director | 83,746 | 0.03% | Jun 18, 2026 |
| Onaiza Cadoret-Manier | Director | 178,156 | 0.07% | Jun 18, 2026 |
| David M. Mott | Director | 9,887,572 | 3.97% | Jun 18, 2026 |
| Richard J. Rodgers | Director | 439,998 | 0.18% | Jun 18, 2026 |
| Muna Bhanji | Director | 163,808 | 0.07% | Jun 18, 2026 |
| William C. Bertrand JR | Director | 303,052 | 0.12% | Jun 18, 2026 |
| Robert B. Bazemore | Director | 68,006 | 0.03% | Jun 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Raab President & CEO, Director | Aug 21, 2026 | Sale | −8,411 | $3.86 | $32.47K | 1,638,970 |
| Michael Raab President & CEO, Director | Aug 21, 2026 | Sale | −15,976 | $3.86 | $61.67K | 1,647,381 |
| Michael Raab President & CEO, Director | Aug 21, 2026 | Sale | −19,178 | $3.86 | $74.03K | 1,619,792 |
| Michael Raab President & CEO, Director | Aug 21, 2026 | Sale | −15,009 | $3.86 | $57.93K | 1,663,357 |
| James Parker Brady Chief Human Resources Officer | Aug 21, 2026 | Sale | −1,976 | $3.86 | $7.63K | 259,090 |
| James Parker Brady Chief Human Resources Officer | Aug 21, 2026 | Sale | −13,160 | $3.86 | $50.80K | 245,930 |
| Joseph James Reilly See Remarks | Aug 21, 2026 | Sale | −2,872 | $3.86 | $11.09K | 146,964 |
| Joseph James Reilly See Remarks | Aug 21, 2026 | Sale | −1,110 | $3.86 | $4.28K | 145,854 |
| Mike Kelliher Chief Business Officer | Aug 21, 2026 | Sale | −2,652 | $3.86 | $10.24K | 351,662 |
| Mike Kelliher Chief Business Officer | Aug 21, 2026 | Sale | −2,002 | $3.86 | $7.73K | 349,660 |
| Mike Kelliher Chief Business Officer | Aug 21, 2026 | Sale | −3,104 | $3.86 | $11.98K | 354,314 |
| Susan Hohenleitner Chief Financial Officer | Aug 21, 2026 | Sale | −1,558 | $3.86 | $6.01K | 227,520 |
| John E. Bishop See Remarks | Aug 21, 2026 | Sale | −2,469 | $3.86 | $9.53K | 317,095 |
| John E. Bishop See Remarks | Aug 21, 2026 | Sale | −17,281 | $3.86 | $66.70K | 319,564 |
| Eric Duane Foster Chief Commercial Officer | Aug 21, 2026 | Sale | −2,575 | $3.86 | $9.94K | 409,410 |
| Eric Duane Foster Chief Commercial Officer | Aug 21, 2026 | Sale | −3,389 | $3.86 | $13.08K | 411,985 |
| Eric Duane Foster Chief Commercial Officer | Aug 21, 2026 | Sale | −2,598 | $3.86 | $10.03K | 415,374 |
| Laura A. Williams Chief Patient Officer | Aug 21, 2026 | Sale | −3,089 | $3.86 | $11.92K | 371,620 |
| Laura A. Williams Chief Patient Officer | Aug 21, 2026 | Sale | −2,430 | $3.86 | $9.38K | 369,190 |
| Laura A. Williams Chief Patient Officer | Aug 21, 2026 | Sale | −1,734 | $3.86 | $6.69K | 367,456 |
| Laura A. Williams Chief Patient Officer | Aug 21, 2026 | Sale | −3,486 | $3.86 | $13.46K | 374,709 |
| Michael Raab President & CEO, Director | Jul 15, 2026 | Option exercise | +20,834 | $0.99 | $20.63K | 1,720,034 |
| Michael Raab President & CEO, Director | Jul 15, 2026 | Sale(10b5-1 plan) | −41,668 | $5.06 | $210.84K | 1,678,366 |
| Laura A. Williams Chief Patient Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −81,898 | $5.99 | $490.57K | 378,195 |
| Laura A. Williams Chief Patient Officer | Jun 18, 2026 | Option exercise | +31,000 | $0.99 | $30.69K | 460,093 |
| Richard J. Rodgers Director | Jun 16, 2026 | Award | +26,455 | – | – | 439,998 |
| Robert B. Bazemore Director | Jun 16, 2026 | Award | +26,455 | – | – | 68,006 |
| William C. Bertrand JR Director | Jun 16, 2026 | Award | +12,345 | – | – | 303,052 |
| William C. Bertrand JR Director | Jun 16, 2026 | Award | +26,455 | – | – | 329,507 |
| Onaiza Cadoret-Manier Director | Jun 16, 2026 | Award | +26,455 | – | – | 178,156 |
| Muna Bhanji Director | Jun 16, 2026 | Award | +26,455 | – | – | 163,808 |
| Merdad Parsey Director | Jun 16, 2026 | Award | +26,455 | – | – | 83,746 |
| David M. Mott Director | Jun 16, 2026 | Award | +20,282 | – | – | 3,323,200 |
| David M. Mott Director | Jun 16, 2026 | Award | +26,455 | – | – | 3,349,655 |
| Michael Raab President & CEO, Director | Jun 15, 2026 | Sale(10b5-1 plan) | −41,666 | $5.67 | $236.25K | 1,699,200 |
| Michael Raab President & CEO, Director | Jun 15, 2026 | Option exercise | +20,833 | $0.99 | $20.62K | 1,740,866 |
| Joseph James Reilly See Remarks | May 21, 2026 | Sale | −1,036 | $6.27 | $6.50K | 149,836 |
| Joseph James Reilly See Remarks | May 21, 2026 | Sale | −2,683 | $6.27 | $16.82K | 149,107 |
| James Parker Brady Chief Human Resources Officer | May 21, 2026 | Sale | −1,846 | $6.27 | $11.57K | 261,066 |
| Susan Hohenleitner Chief Financial Officer | May 21, 2026 | Sale | −1,455 | $6.27 | $9.12K | 229,078 |
| Laura A. Williams Chief Patient Officer | May 21, 2026 | Sale | −2,157 | $6.27 | $13.52K | 432,422 |
| Laura A. Williams Chief Patient Officer | May 21, 2026 | Sale | −1,503 | $6.27 | $9.42K | 434,579 |
| Laura A. Williams Chief Patient Officer | May 21, 2026 | Sale | −1,911 | $6.27 | $11.98K | 430,511 |
| Laura A. Williams Chief Patient Officer | May 21, 2026 | Sale | −1,418 | $6.27 | $8.89K | 429,093 |
| Mike Kelliher Chief Business Officer | May 21, 2026 | Sale | −2,478 | $6.27 | $15.54K | 357,418 |
| Mike Kelliher Chief Business Officer | May 21, 2026 | Sale | −1,870 | $6.27 | $11.72K | 359,896 |
| Mike Kelliher Chief Business Officer | May 21, 2026 | Sale | −2,900 | $6.27 | $18.18K | 361,766 |
| John E. Bishop See Remarks | May 21, 2026 | Sale | −2,306 | $6.27 | $14.46K | 336,845 |
| Michael Raab President & CEO, Director | May 21, 2026 | Sale | −14,933 | $6.27 | $93.63K | 1,759,848 |
| Michael Raab President & CEO, Director | May 21, 2026 | Sale | −7,861 | $6.27 | $49.29K | 1,751,987 |
| Michael Raab President & CEO, Director | May 21, 2026 | Sale | −17,926 | $6.27 | $112.40K | 1,734,061 |
| Michael Raab President & CEO, Director | May 21, 2026 | Sale | −14,028 | $6.27 | $87.96K | 1,720,033 |
| Eric Duane Foster Chief Commercial Officer | May 21, 2026 | Sale | −2,405 | $6.27 | $15.08K | 417,972 |
| Eric Duane Foster Chief Commercial Officer | May 21, 2026 | Sale | −3,166 | $6.27 | $19.85K | 422,804 |
| Eric Duane Foster Chief Commercial Officer | May 21, 2026 | Sale | −2,427 | $6.27 | $15.22K | 420,377 |
| Michael Raab President & CEO, Director | May 15, 2026 | Option exercise | +20,833 | $0.99 | $20.62K | 1,816,447 |
| Michael Raab President & CEO, Director | May 15, 2026 | Sale(10b5-1 plan) | −41,666 | $6.28 | $261.66K | 1,774,781 |
| Michael Raab President & CEO, Director | Apr 15, 2026 | Sale(10b5-1 plan) | −41,668 | $6.29 | $262.09K | 1,795,614 |
| Michael Raab President & CEO, Director | Apr 15, 2026 | Option exercise | +20,834 | $0.99 | $20.63K | 1,837,282 |
| Michael Raab President & CEO, Director | Mar 16, 2026 | Option exercise | +20,833 | $0.99 | $20.62K | 1,856,986 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ardelyx's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,778 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Susan Hohenleitner Officer | Aug 21, 2026 | 2,650 | $10.68K | Aug 21, 2026 | Vesting of restricted stock units |
| Mike Kelliher Officer | Aug 21, 2026 | 10,500 | $42.32K | Aug 21, 2026 | Vesting of restricted stock units |
| Michael Raab Officer | Aug 21, 2026 | 44,500 | $179.34K | Aug 21, 2026 | Vesting of restricted stock units |
| Eric Duane Foster Officer | Aug 21, 2026 | 11,900 | $47.96K | Aug 21, 2026 | Vesting of restricted stock units |
| Laura A. Williams Officer | Aug 21, 2026 | 10,500 | $42.32K | Aug 21, 2026 | Vesting of restricted stock units |
| Joseph James Reilly Officer | Aug 21, 2026 | 4,700 | $18.94K | Aug 21, 2026 | Vesting of restricted stock units |
| John E. Bishop Officer | Aug 21, 2026 | 25,500 | $102.77K | Aug 21, 2026 | Vesting of restricted stock units |
| James Parker Brady Officer | Aug 21, 2026 | 19,700 | $79.39K | Aug 21, 2026 | Vesting of restricted stock units |
| Laura A. Williams Officer | Jun 18, 2026 | 81,898 | $478.28K | Jun 18, 2026 | Exercise of Stock Options |
| Michael Raab Officer, Director | Jun 17, 2026 | 41,666 | $236.66K | Jun 15, 2026 | Exercise of Stock Options |
| Michael Raab Director, Officer | Jun 15, 2026 | 125,000 | $711.25K | Jun 15, 2026 | Exercise of Stock Options |
| John E. Bishop Officer | May 19, 2026 | 3,700 | $23.05K | May 19, 2026 | Vesting of restricted stock units |
| Michael Raab Officer | May 19, 2026 | 44,500 | $277.24K | May 19, 2026 | Vesting of restricted stock units |
| Joseph James Reilly Officer | May 19, 2026 | 4,700 | $29.28K | May 19, 2026 | Vesting of restricted stock units |
| Eric Duane Foster Officer | May 19, 2026 | 11,900 | $74.14K | May 19, 2026 | Vesting of restricted stock units |
See a number that looks wrong?